Moderna has teamed up with OpenAI to bring its GPT technology to drug development.
The collaboration, which a Moderna spokesperson said began in May 2023 and was not disclosed previously, has allowed the company to get up to “80% internal adoption” using a tweaked version of the popular ChatGPT, according to a press release. Moderna is now using GPTs across a variety of sections in its business. Terms of the deal will not be disclosed Wednesday, the spokesperson confirmed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.